Integrated cardiac safety assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance /
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awdur Corfforaethol: | |
| Awduron Eraill: | |
| Fformat: | Electronig eLyfr |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
Hoboken, N.J. :
John Wiley & Sons,
c2009.
|
| Pynciau: | |
| Mynediad Ar-lein: | An electronic book accessible through the World Wide Web; click to view |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Tabl Cynhwysion:
- The importance of cardiac safety assessments
- The biological basis of adverse drug reactions
- Cardiac structure and function
- Cardiac pathophysiology and disease
- Drug discovery and drug design
- Nonclinical development
- The thorough QT/QTc trial
- General safety assessments
- Therapeutic use trials and meta-analyses
- Assessment methodologies in nonexperimental postmarketing surveillance
- Postmarketing proarrhythmic cardiac safety assessments
- Generalized cardiac safety
- Medication errors, adherence, and concordance
- Future directions in drug safety.